Novo Nordisk suspended from industry body over serious breachesBMJ 2023; 380 doi: https://doi.org/10.1136/bmj.p634 (Published 17 March 2023) Cite this as: BMJ 2023;380:p634
- Jacqui Wise
The Danish pharmaceutical company Novo Nordisk has been suspended as a member of the Association of the British Pharmaceutical Industry (ABPI) for two years because of “serious breaches” of the organisation’s code of practice.1
The company failed to disclose clearly its sponsorship of a weight management training course for healthcare professionals which included positive information on its obesity drug Saxenda (liraglutide).
The course, promoted on LinkedIn, was offered by a third party training provider and Novo Nordisk said it had supported it “at arm’s length.” ABPI said, however, that it was concerned that Novo Nordisk did not recognise that this was a large scale Saxenda promotional campaign which the company had knowingly paid for and which was “disguised.”
Novo Nordisk also covered the cost of provision of a patient group direction (PGD) to prescribe Saxenda to those health professionals who had …
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.